Penumbra

Penumbra's 15-min chart signals RSI overbought, KDJ death cross.

Boston Scientific

Boston Scientific's $14.5B Acquisition of Penumbra: A Strategic Move to Enter New Markets

Green Dot

Fonar

Investigation of Penumbra, FONAR, Green Dot for potential securities law violations.

Penumbra Triggers MACD Death Cross and KDJ Death Cross on 15-Minute Chart

Penumbra: RBC Downgrades to Sector Perform, Raises PT to $374.

Catalyst<ul> <li>Multiple recent Long Lower Shadow technical signals in early January indicate strong bullish momentum for PEN.</li> <li>Fund flows show positive inflows across all order size buckets, suggesting growing institutional interest.</li> <li>Analysts maintain a Strong Buy rating despite mostly Neutral sentiment, reflecting some institutional optimism.</li></ul>Risk<ul> <li>Recent MACD Death Cross and Golden Cross signals in late December and mid-January show conflicting bearish and bullish trends, indicating market uncertainty.</li> <li>Technical indicators reveal a weak overall trend, with analysts suggesting caution due to volatile and unclear market direction.</li></ul>

Key Factors

Penumbra (PEN) closed with a 0.63% gain on $1 billion volume amid ongoing merger developments. Boston Scientific's $14.5 billion acquisition of Penumbra is expected to close in 2026. An investigation is underway into Penumbra's sale to Boston Scientific for potential securities law violations.

Recent Updates

PEN News